Blueprint is also eligible to receive up ... and Taiwan), where it has a partnership with CStone Pharmaceuticals. In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil ...

Blueprint Medicines' AYVAKIT leads its revenue growth, while its pipeline targets multiple cancers. Read why BPMC stock is a ...

J.P. Morgan said its top biotech picks for 2025 were Vertex, Travere, SpringWorks, PTC Therapeutics, Wave Life Sciences, ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Steris (STE – Research Report), Benitec ...

JP Morgan initiates coverage on Blueprint Medicines, highlighting Ayvakit's significant growth, 2024 revenue forecast, and potential strategic opportunities. Vandana Singh C.H. Robinson Worldwide ...

Blueprint’s lead drug Ayvakit’s sales ... The gene therapy has been developed in collaboration with Vertex Pharmaceuticals. CRISPR currently carries a Zacks Rank #2. The loss per share ...

Blueprint Medicines anticipates approximately $475 million to $480 million in global Ayvakit net product revenues in 2024, an increase from $435 million to $450 million in the previous range. This ...

Chairman of Egyptian Pharmaceutical City Amr Mamdouh said that Egypt has all the necessary qualifications to pioneer in the pharmaceutical localization field and enhance local production ...